Cargando…
Risk for contralateral breast cancer among carriers of the CHEK2(*)1100delC mutation in the WECARE Study
The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2(*)1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2(*)1100delC mutation carrier status increases the risk for asynchronous contralateral breast c...
Autores principales: | Mellemkjær, L, Dahl, C, Olsen, J H, Bertelsen, L, Guldberg, P, Christensen, J, Børresen-Dale, A-L, Stovall, M, Langholz, B, Bernstein, L, Lynch, C F, Malone, K E, Haile, R W, Andersson, M, Thomas, D C, Concannon, P, Capanu, M, Boice, J D, Bernstein, J L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259175/ https://www.ncbi.nlm.nih.gov/pubmed/18253122 http://dx.doi.org/10.1038/sj.bjc.6604228 |
Ejemplares similares
-
Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study
por: Teraoka, Sharon N, et al.
Publicado: (2011) -
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
por: Kriege, M, et al.
Publicado: (2014) -
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis
por: Koppert, L B, et al.
Publicado: (2004) -
Genetic modifiers of CHEK2*1100delC associated breast cancer risk
por: Muranen, Taru A., et al.
Publicado: (2016) -
Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study
por: Langballe, Rikke, et al.
Publicado: (2016)